title: Heart failure due to left ventricular systolic dysfunction: treatment at discharge from hospital and at one year.
abstract: BACKGROUND
  The treatment of heart failure (HF) due to left ventricular systolic dysfunction has been defined in recent guidelines, but these guidelines are not always applied in routine clinical practice. One of the objectives of the ETICS study was to evaluate medical treatment at discharge and after 1 year in patients hospitalised for a first episode of congestive HF due to left ventricular systolic dysfunction in 2000.
  
  
  METHODS
  One hundred and seventy nine patients (63% males, mean age of 69+/-13 years) with an ejection fraction < or = 40% were prospectively included. The main aetiology was ischaemic heart disease (44%).
  
  
  RESULTS
  The drugs prescribed at discharge and at one year, respectively, were loop diuretics in 95% and 91% of cases, angiotensin-converting enzyme (ACE) inhibitors in 82% and 75%, spironolactone in 35% and 37%, beta-blockers in 25% and 41%, digitalis glycosides in 34% and 30% of cases, and nitrates in 20% and 16% of cases. ACE inhibitors were prescribed at discharge and at 1 year at dosages reaching 64+/-29% and 72+/-30% of the recommended doses, respectively, and beta-blockers were prescribed at 26+/-16% and 35+/-25% of recommended doses, respectively.
  
  
  CONCLUSIONS
  Diuretics and ACE inhibitors are largely prescribed in HF due to left ventricular systolic dysfunction, followed by spironolactone. Beta-blockers are still underused both in terms of the rate of patients receiving them and the daily doses. These results highlight the value of continuing to widely circulate official practice guidelines in order to improve the management of HF due to left ventricular systolic dysfunction.
authors.affiliation: Department of Cardiology, South Hospital, Amiens, France.
authors.forename: D
authors.initials: D
authors.lastname: Houpe
authors.forename: M
authors.initials: M
authors.lastname: Peltier
authors.forename: A
authors.initials: A
authors.lastname: Cohen-Solal
authors.forename: M
authors.initials: M
authors.lastname: Béguin
authors.forename: F
authors.initials: F
authors.lastname: Lévy
authors.forename: M
authors.initials: M
authors.lastname: Slama
authors.forename: K
authors.initials: K
authors.lastname: Chapelain
authors.forename: C
authors.initials: C
authors.lastname: Tribouilloy
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D019538:Health Care Surveys; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians'; D013148:Spironolactone / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000150:complications
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D013148:Spironolactone